全球生物样本库市场：按产品类型、按生物样本类型、按生物样本库类型、按服务、按应用、按地区和预测

生物库市场规模及预测

2024 年生物银行市场规模价值 711.4 亿美元，预计到 2032 年将达到 1,091.8 亿美元，2026 年至 2032 年的复合年增长率为 5.50%。

生物库储存生物样本、遗传资讯、健康记录和其他相关数据，以供潜在的研究应用。

生物样本库在生物医学研究中发挥着至关重要的作用，它使研究人员能够获得来自不同人群的大量、特征明确的样本。它们可用于研究疾病的遗传易感性、开发个人化医疗治疗方法，以及研究环境对人类健康的影响。

未来的生物样本库有望透过拥抱人工智慧和区块链等现代技术来拓宽视野，从而更好地管理和分析数据。这项变革将促进跨研究领域的伙伴关係，加速生物标记的发现，协助个人化药物开发，并最终改变精准医疗和医疗保健创新的未来。

全球生物样本库市场动态

影响全球生物银行市场的关键市场动态是：

关键市场驱动因素

个人化医疗需求日益增长：个人化医疗需求日益增长：过去十年，个人化医疗的需求持续成长。虽然目前尚无确切数据，但众多医学协会和研究机构已註意到市场对此领域的兴趣日益浓厚。精准医疗市场预计将大幅扩张，一些预测显示，2020年至2025年的复合年增长率将达到10-12%。

生物标记研究日益​​受到关注：近年来，生物标记研究取得了显着进展。全球生物标记市场正在蓬勃发展，一些预测显示，2019年至2024年的复合年增长率将达到13-15%。製药和生物技术行业研发支出的增加、癌症发生率的上升以及诊断技术的进步推动了这一增长。

生物医学研究和药物开发的成长：生物样本库帮助製药和生物技术公司加速药物发现和开发流程。研究人员可以利用丰富的生物资讯来识别新的药物标靶、检验治疗方法方案并优化临床试验设计，从而缩短新药上市时间和降低成本。

技术进步：样本采集、储存和管理领域的技术进步显着提高了生物样本库的效率和可扩展性。自动化、机器人技术和云端基础技术使生物样本库能够更有效率地储存和检索样本，长期保持样本完整性，并支援全球实验室之间的无缝资料共用。

主要问题

伦理与法律考量：生物样本库必须应对权限、隐私和资料保护等严峻的伦理与法律体制。确保遵守跨司法管辖区的法规，同时维护透明度和捐赠者权利，是一项重大挑战。

永续性和资金：生物样本库需要大量的资金来维护基础设施、储存样本和管理资料。公共和私人生物样本库在确保长期资金和长期永续性的同时，也面临预算约束的持续挑战。

样本品质与标准化：维护样本完整性、确保统一的采集技术、减少分析前的差异性，都是生物样本库建置中的重要议题。样本处理、储存条件和元资料记录的差异会影响研究的可重复性和研究结果的可靠性。

资料整合与相容性：整合来自生物库的各种生物、临床和基因组资料在资料标准、与其他系统的相容性、资料安全等方面带来了技术挑战。资料格式的协调和有效资料共用框架的建立对于最大限度地利用生物库资源进行研究合作和临床应用至关重要。

主要趋势

扩大特定疾病生物库：针对特定疾病或病症（如癌症、心血管疾病、罕见基因异常等）创建专门生物库的趋势日益增长。这些专门的生物库从患有特定疾病的个人收集样本和数据，从而实现更有针对性的研究和个人化治疗的开发。

巨量资料与人工智慧的融合：生物样本库越来越多地使用巨量资料分析和人工智慧 (AI) 从海量资料集中提取有价值的洞察。人工智慧演算法利用来自多个资讯来源的广泛生物和临床数据，帮助识别生物标记、预测病情进展并优化治疗策略。

全球合作与数据共用：生物样本库、研究机构和製药公司正在全球合作。促进资料共用、流程标准化和伦理标准协调的努力，使得人们能够获得多样化的样本集，并加速跨境科学发现。

虚拟生物样本库数位双胞胎的兴起：虚拟生物样本库正日益普及，其数位模型可模拟真实生物样本和资料的属性。这些数数位双胞胎使研究人员无需真实样本即可进行虚拟测试、增强研究设计并预测结果，从而降低成本并提高研究效率。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查方法

第二章执行摘要

• 主要发现
• 市场概览
• 市集亮点

第三章市场概述

• 市场规模和成长潜力
• 市场趋势
• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析

第四章 生物样本库市场（按产品）

• 实验室资讯管理系统（LIMS）
• 生物库设备

5. 生物样本库市场（依生物样本类型）

• 器官
• 干细胞

第六章 生物样本库市场（依生物样本库类型）

• 真实的
• 虚拟的

第七章 生物样本库市场（按服务）

• 生物样本库和储存库
• 实验室处理
• 资格/验证
• 低温运输物流

第 8 章 生物样本库市场（按应用）

• 治疗
• 药物研发与临床研究
• 临床诊断

第九章区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯聯合大公国

第十章 市场动态

• 市场驱动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第十一章竞争格局

• 主要企业
• 市场占有率分析

第十二章 公司简介

• Thermo Fisher Scientific
• Merck KGaA
• QIAGEN
• Hamilton Company
• Avantor
• Tecan
• BD（Becton, Dickinson and Company）
• Promega Corporation
• Brooks Automation
• Biovault Family

第十三章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第十四章 附录

• 简称列表
• 来源和参考文献

Biobanks Market Size and Forecast

Biobanks Market size was valued at USD 71.14 Billion in 2024 and is projected to reach USD 109.18 Billion by 2032, growing at a CAGR of 5.50% from 2026 to 2032.

Biobanks help store biological samples and associated data, such as genetic information and health records, for further application in research.

They play an important role in biomedical research by giving researchers access to vast, well-characterized sample collections from a variety of populations. Biobanks can be used to examine genetic predispositions to diseases, develop personalized medicine treatments, and investigate environmental influences on human health.

In the future, biobanks are expected to broaden their scope by incorporating modern technologies such as artificial intelligence and blockchain for better data administration and analysis. This change will enable greater partnerships across research disciplines, speed biomarker discovery, and aid in the development of tailored medicines, ultimately changing the future of precision medicine and healthcare innovation.

Global Biobanks Market Dynamics

The key market dynamics that are shaping the global biobanks market include:

Key Market Drivers:

Rising Demand for Personalized Medicine: The demand for individualized medication has been gradually increasing during the last decade. While I do not have exact figures, numerous health groups and research institutions have indicated increased interest in this sector. The precision medicine market is expected to expand significantly, with some projections indicating a compound annual growth rate (CAGR) of 10-12% between 2020 and 2025.

Increasing Focus on Biomarker Research: Biomarker research is witnessing significant progress in recent years. The global biomarkers market is rising, with some forecasts predicting a CAGR of 13-15% from 2019 to 2024. This expansion is being driven by causes such as increase in R&D spending in the pharmaceutical and biotechnology industries, rising cancer rates, and advances in diagnostic technologies.

Growth in Biomedical Research and Drug Development: Biobanks help pharmaceutical and biotechnology businesses accelerate medication discovery and development procedures. Researchers can use extensive biological information to identify new drug targets, validate therapeutic ideas, and optimize clinical trial designs, lowering the time and costs associated with bringing new medicines to market.

Technological Advancement: Technological advancements in sample collection, storage, and management have dramatically improved biobank efficiency and scalability. Automation, robots, and cloud-based technologies allow biobanks to store and retrieve samples more efficiently, maintain sample integrity over time, and support seamless data sharing across research institutions around the world.

Key Challenges:

Ethical and Legal Considerations: Biobanks must navigate difficult ethical and legal frameworks related to permission, privacy, and data protection. Ensuring compliance with rules across several jurisdictions while retaining transparency and donor rights presents substantial problems.

Sustainability and Funding: Biobanks require significant financial resources to maintain infrastructure, store samples, and manage data. Both public and private biobanks have continual issues in securing long-term funding while adhering to budget limits and guaranteeing long-term sustainability.

Sample Quality and Standardization: Maintaining sample integrity, assuring uniform collection techniques, and reducing pre-analytical variability are all key problems in biobanking. Variations in sample handling, storage conditions, and metadata recording can have an impact on research reproducibility and the reliability of study results.

Data Integration and Compatibility: Integrating varied biological, clinical, and genomic data from biobanks presents technical issues such as data standards, compatibility with other systems, and data security. Harmonizing data formats and building effective data sharing frameworks are critical for making the most of biobank resources in research collaborations and clinical applications.

Key Trends:

Expansion of Disease-certain Biobanks: There is an increasing trend of creating biobanks dedicated to certain diseases or conditions, such as cancer, cardiovascular disease, and uncommon genetic abnormalities. These specialized biobanks collect samples and data from individuals with specific illnesses, allowing for more focused research and individualized treatment development.

Integration of Big Data and AI: Biobanks are increasingly using big data analytics and artificial intelligence (AI) to extract valuable insights from massive datasets. AI algorithms aid in the identification of biomarkers, disease progression prediction, and treatment strategy optimization using extensive biological and clinical data from numerous sources.

Global Collaboration and Data Sharing Initiatives: Biobanks, research institutes, and pharmaceutical corporations are working together on a global scale. Initiatives that promote data sharing, procedure standardization, and ethical norms harmonization enable greater access to different sample sets and accelerate scientific discoveries across borders.

The Rise of Virtual Biobanks and Digital Twins: Virtual biobanks, in which digital models mimic the properties of genuine biological samples and data, are gaining popularity. These digital twins allow researchers to run virtual tests, enhance study designs, and forecast outcomes without requiring actual samples, lowering costs and increasing research efficiency.

Global Biobanks Market Regional Analysis

Here is a more detailed regional analysis of the global biobanks market:

North America:

North America is anticipated to hold major share in the global biobanks market over the forecast period.

North America has a solid foundation in research and development, with major government and commercial funding supporting biobank activities.

The region has a well-established healthcare infrastructure and a high prevalence of chronic diseases, which increases demand for biospecimens in research to improve diagnosis and treatment.

Furthermore, an increasing emphasis on personalized and precision medicine increases the demand for biobanks in North America. This convergence of circumstances establishes North America as the clear worldwide biobanks industry leader.

Asia Pacific:

In terms of global biobanks market growth, the Asia Pacific region is unquestionably the leader. This rapid increase can be due to a variety of things.

Governments in China, Japan, and South Korea are increasing their investments in R&D. Second, the rising frequency of chronic diseases, combined with a developing healthcare infrastructure, increases the demand for biospecimens utilized in research to improve diagnoses and treatments.

Increasing awareness of the use of biobanks in personalized treatment is moving the market forward. This convergence of circumstances is enabling the Asia Pacific region exhibit fastest growth in the biobank market.

Global Biobanks Market: Segmentation Analysis

The Global Biobanks Market is segmented on the basis of By Product, By Bio Specimen Type, By Biobank Type, By Service and By Application, By Geography.

Biobanks Market, By Product

• Laboratory Information Management System (LIMS)
• Biobanking Equipment

Based on Product, the Global Biobanks Market is segmented into LIMS and Biobanking Equipment. Biobanking Equipment is the largest segment of the global biobanks market, since it includes key tools for sample collection, storage, and preservation. LIMS (Laboratory Information Management Systems) is the fastest-growing market, driven by the increased demand for effective data management, sample tracking, and the incorporation of modern digital technologies into biobanking processes.

Biobanks Market, By Bio Specimen Type

• Organs
• Stem Cells

Based on Bio specimen Type, the Global Biobanks Market is segmented into Organs and Stem Cells. Organs are the most common bio specimen type in the worldwide biobanks market, owing to their vital role in transplant research and other scientific investigations. Stem cells are the fastest-growing segment, owing to their enormous potential in regenerative medicine, disease modeling, and tailored treatment strategies.

Biobanks Market, By Biobank Type

• Real
• Virtual

Based on Biobank Type, the Global Biobanks Market is segmented into Real and Virtual. Real biobanks are the most common form in the global biobanks market, as they were originally established for the physical collection, storage, and management of biological samples. Virtual biobanks are the fastest-growing segment, spurred by advances in digital technologies and rising demand for remote access to biological data for research reasons.

Biobanks Market, By Service

• Biobanking & Repository
• Lab Processing
• Qualification/Validation
• Cold Chain Logistics

Based on Service, the Global Biobanks Market is segmented into Biobanking & Repository, Lab Processing, Qualification/Validation, and Cold Chain Logistics. Biobanking & Repository is the dominating service sector in the global biobanks market, as it is biobanks' primary duty to collect, store, and manage biological samples. Cold Chain Logistics is the fastest-growing market, driven by the growing need to preserve biological samples' integrity throughout transportation and storage under strict temperature control settings.

Biobanks Market, By Application

• Therapeutics
• Drug Discovery & Clinical Research
• Clinical Diagnostics

Based on Application, the Global Biobanks Market is segmented into Therapeutics, Drug Discovery & Clinical Research, and Clinical Diagnostics. Drug Discovery & Clinical Research dominates the worldwide biobanks market, owing to the widespread usage of biobanked samples in the development of novel medications and clinical trials. Clinical Diagnostics is the fastest-growing market, driven by rising demand for precision medicine and the use of biobanks to uncover illness biomarkers and create diagnostic tests.

Biobanks Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on the Geography, the Global Biobanks Market are classified into North America, Europe, Asia Pacific, and Rest of the World. North America dominates the global biobanks market, owing to advanced healthcare infrastructure, significant research funding, and a large number of established biobanks. Asia Pacific is the fastest-growing area, driven by increased healthcare spending, increased awareness of customized treatment, and the expansion of biobank projects.

Key Players

The "Global Biobanks Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Thermo Fisher Scientific, Merck KGaA, QIAGEN, Hamilton Company, Avantor, BD (Becton, Dickinson and Company), Promega Corporation, Brooks Automation, Biovault Family.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Biobanks Market: Recent Developments
• In September 2023, Sheikh Khaled bin Mohamed, Abu Dhabi's Crown Prince, has approved plans to use human stem cells and tissues to conduct personalized medical research. He approved the plan during a meeting of the Abu Dhabi Executive Council. Members of Abu Dhabi's Department of Health presented the plans to Sheikh Khaled. According to the Abu Dhabi Media Office, the initiative would establish a biobank to enable the provision of personalised medicine through innovative treatment programmes that use human stem cells and tissues to conduct medical research.
• In Jun 2022, Mars Petcare today unveiled an unparalleled scientific endeavor aimed at improving understanding of pet health and disease, as well as assisting scientists and veterinarians in developing personalized pet care. The MARS PETCARE BIOBANKTM intends to be the largest and most comprehensive real-world study of its type, collecting 20,000 pets (10,000 dogs and 10,000 cats) from across the United States over a ten-year period.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Biobanks Market, By Product

• Laboratory Information Management System (LIMS)
• Biobanking Equipment

5. Biobanks Market, By Bio Specimen Type

• Organs
• Stem Cells

6. Biobanks Market, By Biobank Type

• Real
• Virtual

7. Biobanks Market, By Service

• Biobanking & Repository
• Lab Processing
• Qualification/Validation
• Cold Chain Logistics

8. Biobanks Market, By Application

• Therapeutics
• Drug Discovery & Clinical Research
• Clinical Diagnostics

9. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

10. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

11. Competitive Landscape

• Key Players
• Market Share Analysis

12. Company Profiles

• Thermo Fisher Scientific
• Merck KGaA
• QIAGEN
• Hamilton Company
• Avantor
• Tecan
• BD (Becton, Dickinson and Company)
• Promega Corporation
• Brooks Automation
• Biovault Family

13. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

14. Appendix

• List of Abbreviations
• Sources and References